Long‑Term Efficacy, Safety, and Guideline Recommendations for Polyethylene Glycol 3350 in Chronic Constipation

Guideline Recommendations

The 2023 AGA‑ACG guidelines give a strong recommendation (moderate‑certainty evidence) for using PEG 3350 as a first‑line pharmacologic therapy in chronic idiopathic constipation, noting that treatment response remains durable for at least 6 months【1】【3】.
PEG 3350 is positioned as a first‑line option, either after adequate fiber supplementation or in combination with fiber, for adults with chronic constipation【1】【2】.

In a pivotal U.S. randomized trial of 304 adults receiving 17 g PEG 3350 daily for 6 months, treatment success was achieved in 52 % of participants versus 11 % with placebo (P < 0.001), demonstrating sustained efficacy【2】.
Long‑term safety data up to 12 months show that PEG 3350 remains effective without evidence of tachyphylaxis, including in an elderly subgroup (≥65 years)【1】【2】.

The most common adverse events are mild gastrointestinal symptoms (abdominal distension, loose stools, flatulence, nausea); these symptoms tend to decrease after the first week of therapy【1】【3】.
Diarrhea incidence with PEG 3350 is not significantly different from placebo in pooled analyses, indicating an acceptable gastrointestinal safety margin【2】.

Initiation: start with 17 g (≈1 heaping tablespoon) of PEG 3350 dissolved in 4–8 oz of liquid; a bowel movement typically occurs within 2–4 days【1】【3】.
Adjunctive fiber: consider adding or preceding PEG 3350 with fiber supplementation for patients with mild constipation【1】【3】.
Duration: continuation beyond the FDA‑approved 2‑week limit is supported by guideline evidence, allowing long‑term maintenance when clinically indicated【1】.
Monitoring: routine laboratory monitoring is not required based on long‑term safety data; clinical assessment of bowel habit suffices【1】.

The FDA label authorizes PEG 3350 only for up to a 2‑week course and warns of possible electrolyte imbalance and laxative dependence with prolonged use【1】.
Clinical trial evidence up to 12 months does not demonstrate electrolyte disturbances or dependence, highlighting a gap between regulatory labeling and real‑world safety data【1】.